Namaste! Ek professional Equity Research Analyst ke taur par, main aapko Jubilant Pharmova Ltd. ka deep fundamental analysis provide kar raha hoon. Ye report strictly verified internet data (Screener.in aur Yahoo Finance) par aadharit hai, jisme current market price, Q3 FY26 (Dec 2025) ke latest quarterly results, aur FY25 tak ke annual statements shamil hain.
1️⃣ Business Model & Work
- Company exactly kya kaam karti hai? Jubilant Pharmova (pehle Jubilant Life Sciences) ek global integrated pharmaceutical company hai. Ye mainly Radiopharma, Allergy Immunotherapy, CDMO (Contract Development & Manufacturing Organization) Sterile Injectables, CRDMO, Generics, aur Proprietary Novel Drugs ke business me operate karti hai. America me inka ek bada radio-pharmacies network bhi hai.
- Revenue ka main source kya hai? Company ka major revenue CDMO Sterile Injectables aur Radiopharma segment se aata hai.
- Domestic vs Export exposure: Inka exposure heavily international markets (especially USA aur Canada) ki taraf hai. (Exact % split dono primary sources par easily available nahi hai, isliye exact split DATA NOT AVAILABLE / NOT CONFIRMED).
- Industry me role & competitive advantage: Inka US me strong manufacturing base (Spokane facility) aur specialized Radiopharma capabilities inka sabse bada competitive advantage hai. CDMO space me sterile injectables ki high demand inko market me ek strong player banati hai.
2️⃣ Industry & Sector Analysis
- Sector ka current status (India focused): Pharmaceuticals & Healthcare sector abhi CDMO (Contract Manufacturing) theme par heavy focus kar raha hai. Global pharma companies apni manufacturing India aur dusre cost-effective regions me outsource kar rahi hain.
- Sector cyclical ya secular? Ye sector Secular hai. Healthcare, medicines aur diagnostic imaging products ki demand economic cycle par zyada depend nahi karti, balki structural demand (aging population, chronic diseases) par aadharit hoti hai.
- Growth drivers & government policies: China-Plus-One strategy aur Indian Government ki Pharma PLI (Production Linked Incentive) schemes is sector ke major tailwinds hain.
- Major competitors: Divi’s Laboratories, Torrent Pharma, Cipla, Dr. Reddy’s Lab, Lupin, aur Zydus Lifesciences (Market cap aur specific segments me variation hai).
3️⃣ Latest Financial Performance (STRICT DATA RULE)
Niche diya gaya consolidated financial data Screener.in se FY21 se FY25 tak aur latest Dec 2025 (Q3 FY26) quarter ka hai. (All figures in ₹ Crores, except percentages).
| Period (FY / Quarter) | Sales/Revenue | Operating Profit | OPM % | Net Profit (PAT) | EPS (₹) |
| FY21 | 6,099 | 1,403 | 23% | 836 | 52.47 |
| FY22 | 6,130 | 1,150 | 19% | 413 | 25.98 |
| FY23 | 6,282 | 779 | 12% | -65 (Loss) | -3.83 |
| FY24 | 6,703 | 901 | 13% | 73 | 4.84 |
| FY25 | 7,234 | 1,173 | 16% | 836 | 52.69 |
| Dec 2025 (Q3 FY26) | 2,122 | 289 | 14% | 56 | 3.51 |
Key Ratios & Balance Sheet Data (Latest):
- ROE (Return on Equity): 9.55% (Screener.in)
- ROCE (Return on Capital Employed): 9.54% (Screener.in)
- Debt/Equity Ratio: ~0.44 (Groww/Yahoo)
- Interest Coverage: Company TTM basis par ₹208 Cr interest pay karti hai, aur operating profit ₹1,266 Cr hai, jisse interest coverage ratio decent (~6x) banta hai.
- Free Cash Flow trend & quality: DATA NOT AVAILABLE / NOT CONFIRMED in pure exact historical format from primary summary, halanki Operating Cash Flow (CFO) historically positive raha hai.
4️⃣ Management & Shareholding (Latest Only – Dec 2025)
- Promoter holding: 47.68% (Promoter holding stable hai).
- Pledged Shares: 5.40% shares pledged hain (Ye ek minor red flag hai).
- FII Holding: 15.96% – 16.0%
- DII / Mutual Fund holding: Mutual Funds 7.69% aur overall DII ~11.2% hold karte hain. FII/DII ka mila kar substantial (approx 27%) institutional holding hai.
- Management track record: Bhartia Group (Jubilant Group) ki company hai. Management expansion me aggressive hai (US CDMO expansion), halanki regulatory (US FDA) compliance me kabhi-kabhi issues aate hain.
5️⃣ Valuation (Latest Market Data Only)
- Current Market Price (CMP): ~₹868 – ₹873 (As of 20-22 Feb 2026)
- Market Cap: ~₹13,839 – ₹13,900 Crore
- Current PE Ratio: 29.57 (Screener) / 32.22 (Yahoo Finance) -> DATA SOURCE DIFFERENCE OBSERVED
- PB Ratio (Price to Book): 2.10 (Groww/Yahoo) / 2.21 (Screener) -> DATA SOURCE DIFFERENCE OBSERVED
- EV/EBITDA: ~13.37
- Dividend Yield: 0.57%
Peer Comparison (PE Ratio based on Screener):
- Divi’s Lab: 66.08
- Torrent Pharma: 62.04
- Sun Pharma: 34.05
- Cipla: 22.70
- Jubilant Pharmova: ~29.57
Fair Value Approach: Relative valuation ke aadhar par Jubilant Pharmova apni category me fairly valued lagti hai. Ye top-tier CDMO/Pharma players (Divi’s) se kafi sasti hai, lekin generic players ke aas-paas trade kar rahi hai.
6️⃣ Future Growth Triggers (3–5 Years)
- US Capacity Expansion: Company apne US (Spokane) facility me CDMO sterile injectables capacity ko double karne ke liye $300 Million ka capex kar rahi hai (FY28 tak). Nayi high-speed fill & finish line shuru ho chuki hai.
- Vision 2030: Management ne long-term target rakha hai ki aane wale saalon me apni revenue ko double kiya jaye, jisme CDMO aur Radiopharma major drivers rahenge.
- Margin Expansion: Nayi lines par utilization badhne se fixed costs cover hongi, jo aane wale 2-3 saalon me margins improve kar sakti hain.
7️⃣ Present Situation (Current Outlook)
- Stock ka current phase: Stock apne 52-week high (₹1,250) se kafi correct ho kar ₹868 ke level par trade kar raha hai.
- Recent developments ka impact: Dec 2025 (Q3 FY26) results me revenue 17% YoY badha (due to new CDMO line), par Net Profit me bada drop (₹56 Cr) dekhne ko mila. Iska main karan US FDA observations ke chalte Montreal facility ka temporary shutdown aur ₹443 million ka exceptional remediation cost tha.
- Short-term outlook: Margins par facility shutdown aur FDA remediation cost ka dabav raha hai. Jab tak Montreal facility ka issue completely resolve nahi hota, stock me volatility rah sakti hai.
- Long-term outlook: US capex plan aur CDMO demand ko dekhte hue long-term trajectory strong dikhti hai.
8️⃣ Risk & Red Flags
- Regulatory Risks (US FDA): Pharma sector ka sabse bada risk. Haal hi me Montreal facility par FDA observations aur temporary shutdown iska direct example hai, jisse Q3 ka profit sharply gira.
- Financial Volatility: FY23 me company loss (-₹65 Cr) me chali gayi thi aur ab Q3 FY26 me margins dobara dabav me hain. Consistent earnings na hona ek negative point hai.
- Promoter Pledge: 5.40% promoter holding pledged hai, jise closely monitor karna zaroori hai.
- Return Ratios: Single-digit ROE aur ROCE (~9.5%) ek pharma/CDMO company ke standard se kam hai. Top players ka ROCE 20%+ hota hai.
9️⃣ Final Verdict
- Jubilant Pharmova ek high-potential lekin high-regulatory-risk CDMO/Pharma play hai.
- Revenue growth solid hai, par profitability volatile hai. US FDA ke issues inke margins ko lagatar hit kar rahe hain.
- Conservative Investor Suitability: Low. Inconsistent return ratios (ROE < 10%) aur US FDA regulatory shocks conservative investors ke liye suitable nahi hain. Sun Pharma ya Cipla jaise large caps zyada stable hain.
- Aggressive Investor Suitability: Medium to High. Agar aap ek turnaround / capacity expansion growth story me vishwas rakhte hain, toh ₹1,250 se correction ke baad ye current levels par attractive lag sakta hai.
- Approximate Target Range & Risk-Reward: Short-term me stock sideways rah sakta hai jab tak next quarter (Q4) me production normal hokar margins recover nahi hote. Assumption: Agar FY28 tak $300M ka capex full capacity par chalta hai aur koi naya FDA issue nahi aata, toh ye aane wale 2-3 saalon me apne 52-week high ko wapas test kar sakta hai.